Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines

doi:10.5246/jcps.2023.02.009

Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (2): 112-121.DOI: 10.5246/jcps.2023.02.009

• Drug administration and clinical pharmacy column • Previous Articles Next Articles

Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines

Jia Ge¹^,^#, Longfei Chen¹^,^#, Xiaoyan Nie², Jing Chen²^,^*()

1 Reexamination and Invalidation Department of the Patent Office, China National Intellectual Property Administration (CNIPA), Beijing 100088, China
2 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Peking University Health Science Center, Beijing 100191, China

Received:2022-10-21 Revised:2022-11-12 Accepted:2022-11-30 Online:2023-02-28 Published:2023-02-28
Contact: Jing Chen
About author:
# Jia Ge and Longfei Chen contributed equally to this work.

Abstract

Supporting:

Jia Ge, Longfei Chen, Xiaoyan Nie, Jing Chen. Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 112-121.

Figures/Tables 11

Table 1. Chinese patentees of LNP delivery-mRNA vaccine.

References 10

[1]	Li, M.; Wang, H.; Tian, L.; Pang, Z.; Yang, Q.; Huang, T.; Fan, J.; Song, L.; Tong, Y.; Fan, H. COVID-19 vaccine development: milestones, lessons and prospects. Signal. Transduct. Target. Ther. 2022, 7, 146.
[2]	Frost & Sullivan report, Research Report on the Status Quo and Future Development of the Nucleic Acid Drug Market, May 20^th, 2022.
[3]	Hou, X.C.; Zaks, T.; Langer, R.; Dong, Y.Z. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021, 6, 1078–1094.
[4]	Yang, J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert. Rev. Clin. Pharmacol. 2019, 12, 95–99.
[5]	Bureau de l’Économie et du Commerce de l’Ambassade de la République Populaire de Chine en République Française, Sanofi acquires Translate BIO for $3.2 billion, http://www.mofcom.gov.cn/article/i/jyjl/m/202108/ 20210803184559.shtml, August 06^th, 2021.
[6]	Liu, X.Q.; Li, Y.H.; Wang, Z.F.; Cao, S.C.; Huang, W.J.; Yuan, L.; Huang, Y.J.; Zheng, Y.; Chen, J.J.; Ying, B.; Xiang, Z.Y.; Shi, J.; Zhao, J.C.; Huang, Z.; Qin, C.F. Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. Cell Res. 2022, 32, 777–780.
[7]	China became the third country to have approved a mRNA vaccine for marketing, https://www.163.com/dy/article/HIMGUIQQ0552ADWT.html, October 02^nd, 2022.
[8]	Shores, D.; Vivian, T.; Sheena, W. mRNA Patent and Competitive Landscape: 2021 year in Review and 2022 outlook, https://www.rfemerge.com/2022/01/03/mrna-patent-and-competitive-landscape-2021-in-review-and-2022-outlook/, January 3^rd, 2022.
[9]	Xin, X.B. Overview of current mRNA-related patent litigation in the United States, Frontiers of Intellectual Property Public Account, https://mp.weixin.qq.com/s/uXDyOlMRszFGserD0MHXOg, September 14^th, 2022.
[10]	LPP Delivery Platform, Siwei (Shanghai) Biotechnology Co., Ltd. official website, http://www.stemirna.com/lpp/index.aspx.

Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 10

Related Articles 0

Recommended Articles

Metrics

Comments